Search research articles
Contact Us
Filters
Showing results (221-230 of 257) with videos related to
Page
of 26
Sort By:
Nature Medicine
|
February 5, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Saad Z Usmani, Thierry Facon, Vania Hungria, et al.
The New England Journal of Medicine
|
June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Blood Advances
|
February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Sarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Blood
|
March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Jill Corre, Laure Vincent, Philippe Moreau, et al.
Blood Advances
|
September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Sarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood Advances
|
May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE
Nizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Blood
|
January 9, 2007
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau, Michel Attal, Philippe Moreau, et al.
Leukemia
|
May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Michel Delforge, Thierry Facon, et al.
Blood
|
September 22, 2005
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Thierry Facon, Jean-Yves Mary, Brigitte Pégourie, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 257) with videos related to
Sort By:
Page
of 26
Nature Medicine
|
February 5, 2025
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
Saad Z Usmani, Thierry Facon, Vania Hungria, et al.
The New England Journal of Medicine
|
June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Blood Advances
|
February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Sarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Blood
|
March 24, 2025
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
Jill Corre, Laure Vincent, Philippe Moreau, et al.
Blood Advances
|
September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study
Sarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Blood Advances
|
May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE
Nizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Blood
|
January 9, 2007
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau, Michel Attal, Philippe Moreau, et al.
Leukemia
|
May 4, 2018
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Michel Delforge, Thierry Facon, et al.
Blood
|
September 22, 2005
Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
Thierry Facon, Jean-Yves Mary, Brigitte Pégourie, et al.
Page
of 26